Page 143 - Human Use News Today

-- NMOSD is a devastating autoimmune disease of severe and recurrent central nervous system attacks which can result in blindness, paralysis and death -- -- UPLIZNA is indicated as monotherapy for

China’s pharmaceutical market operates under regulations that are closely aligned with world standards, and the companies making innovative...

Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) - read this article along with other careers information, tips and advice on BioSpace

Press release content from Business Wire. The AP news staff was not involved in its creation.

21st Austria weekly - Andritz Agrana Valneva 25/04/2022 [pic1]Andritz: International technology group Andritz has received an order from Papierfabriek Doetinchem Netherlands to upgrade the wet sections of its PM1 and PM3 special paper machines. The start-ups are scheduled for 2022. aim investment is improve quality provide basis a possible capacity increase. will deliver ModuScreen HB dilution headbox screens PrimeFlow AT headboxes with PrimeProfiler F control pumps both machines.Andritz:

With comment from Diane Paskiet, chair of the PQRI L&E Working Group, EPR outlines three key exposure-based safety thresholds and explores how the new extractables and leachables (E&Ls) strategy for parenteral drug products was established.

Merck's Keytruda-chemotherapy combo could soon be approved to treat cervical cancer in the European Union.

The Centers for Disease Control and Prevention (CDC) earlier this spring recommended women who are pregnant, recently pregnant, who are ...

Merck's Keytruda-chemotherapy combo could soon be approved to treat cervical cancer in the European Union.

Sanofi continues to deliver strong business EPS(1) growth driven by higher sales and improved margins in Q1 Paris, April 28, 2022 Q1 2022 sales growth of 8.6% at CER driven by Dupixent and CHC